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ABSTRACT
Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid 
(ATRA) is the first example of targeted therapy. In fact, the oncogenic fusion-protein 
(PML-RAR) typical of this leukemia contains the retinoid-nuclear-receptor RARα. 
PML-RAR is responsible for the differentiation block of the leukemic blast. Besides 
PML-RAR, two endogenous RARα proteins are present in APL blasts, i.e. RARα1 and 
RARα2. We developed different cell populations characterized by PML-RAR, RARα2 
and RARα1 knock-down in the APL-derived NB4 cell-line. Unexpectedly, silencing 
of PML-RAR and RARα2 results in similar increases in the constitutive expression 
of several granulocytic differentiation markers. This is accompanied by enhanced 
expression of the same granulocytic markers upon exposure of the NB4 blasts to 
ATRA. Silencing of PML-RAR and RARα2 causes also similar perturbations in the whole 
genome gene-expression profiles of vehicle and ATRA treated NB4 cells. Unlike PML-
RAR and RARα2, RARα1 knock-down blocks ATRA-dependent induction of several 
granulocytic differentiation markers. Many of the effects on myeloid differentiation 
are confirmed by over-expression of RARα2 in NB4 cells. RARα2 action on myeloid 
differentiation does not require the presence of PML-RAR, as it is recapitulated also 
upon knock-down in PML-RAR-negative HL-60 cells. Thus, relative to RARα1, PML-
RAR and RARα2 exert opposite effects on APL-cell differentiation. These contrasting 
actions may be related to the fact that both PML-RAR and RARα2 interact with and 
inhibit the transcriptional activity of RARα1. The interaction surface is located in 
the carboxy-terminal domain containing the D/E/F regions and it is influenced by 
phosphorylation of Ser-369 of RARα1.
INTRODUCTION
Acute-promyelocytic-leukemia (APL) is characterized 
by a t(15:17) chromosomal translocation involving PML 
and RARA, which results in the expression of the oncogenic 
PML-RAR fusion protein [1–3] and a block in the myeloid 
maturation pathway [4]. The cyto-differentiating agent all-
trans retinoic acid (ATRA) is used in the treatment of APL 
and it has changed the natural history of the disease [5–9].
The biological action of ATRA is mediated by 
RAR and RXR nuclear receptors (NRs). RARα, RARβ, 
RARγ, RXRα, RXRβ and RXRγ are ligand-activated 
transcription-factors controlling the expression of target 
genes [10, 11]. The NR active forms consist of RAR/RXR 
heterodimers, in which the RAR moiety is responsible 
for ligand-binding [12–16]. ATRA binds/activates RARα, 
RARβ and RARγ with the same efficiency [17, 18]. 
The ligand-binding region of RARs is located in the 
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carboxy-terminal E-domain, which is maintained in PML-
RAR (Supplementary Figure S1).
The molecular mechanisms underlying the 
differentiation block afforded by PML-RAR in APL blasts 
and those responsible for ATRA therapeutic activity are 
incompletely defined. PML-RAR may arrest the myeloid 
maturation of APL blasts exerting a dominant-negative 
effect on RARα. Indeed, PML-RAR binds RAREs 
(Retinoic Acid Responsive Elements) of RARα target-
genes [19]. Part of PML-RAR action may also involve 
RARα-independent mechanisms, as the fusion-protein 
binds to a larger set of DNA target-sequences than RARα 
[19]. The relative contribution of PML-RAR and RARα 
to the differentiation process ignited by ATRA in APL 
blasts is also largely unknown. ATRA-induced PML-
RAR degradation may release RARα from the dominant-
negative effect exerted by the fusion-protein, permitting 
its ligand-dependent activation [2, 20, 21]. The situation 
is further complicated by the presence of three different 
RARα isoforms (Supplementary Figure S1).
Using the NB4 model of APL and silencing/over-
expression approaches, we provide evidence that PML-
RAR and the RARα splicing-variant, RARα2, inhibit basal 
and ATRA-dependent myeloid differentiation. In NB4 
cells, knock-down of the major RARα splicing variant, 
RARα1, exerts opposite effects relative to PML-RAR 
and RARα2. RARα2 action on myeloid differentiation is 
recapitulated in PML-RAR-negative and ATRA-sensitive 
HL-60 cells. PML-RAR and RARα2 directly bind/inhibit 
RARα1 transcriptional activity, indicating functional 
antagonism.
RESULTS
RARα2 is expressed, transcriptionally activated 
and degraded by ATRA in the APL-derived NB4 
cell line
Four RARα splicing-variant mRNAs, RARα-v1, 
RARα-v2, RARα-v3 and RARα-v4, are known 
(Supplementary Figure S1). RARα-v1 and RARα-v3 code 
for an identical protein (RARα1). RARα-v4 is translated 
into RARα4 lacking the DNA-binding C-region. RARα2, 
the RARα-v2 product, is devoid of the A-region [22]. We 
determined the levels of PML-RAR and RARα splicing-
variants in NB4 cells grown with and without ATRA 
(Figure 1A). In the absence of ATRA, large amounts of 
PML-RAR mRNA are measurable, while RARAα-v3 
is the major endogenous RARα transcript, followed by 
RARα-v1, RARα-v2 and RARα-v4. PML-RAR and 
RARα-v2 mRNAs are induced by ATRA.
High levels of PML-RAR and RARα proteins are 
highlighted by an antibody [RP-alpha-(F)] recognizing 
the F-region of the two receptors (Figure 1B). Although 
this antibody recognizes both RARα1 and RARα2, the 
RARα bands determined upon Western blot analysis 
(WB) are likely to correspond to RARα1. Indeed, when a 
selective anti-RARα2 antibody [Ab25alpha(A2)] is used, 
a specific RARα2 band is measurable only following 
immuno-precipitation (Figure 1B) or WB analysis with 
high amounts of extracts (see Figure 2C, upper). ATRA-
treated NB4 cells show the expected degradation of 
PML-RAR and RARAα1 proteins, which is associated 
with receptor activation [23, 24] and suppressed by the 
proteasome-inhibitor, MG132 (Figure 1B). Despite 
induction of the corresponding mRNA, the RARα2 protein 
band disappears upon ATRA challenge (Figure 1B). This 
effect is also consequent to proteasome-dependent RARα2 
degradation, since MG132 blocks it (Figure 1B). ATRA 
causes a concentration-dependent stimulation of RARα1, 
RARα2 and PML-RAR transcriptional activity as well 
as a decrease in the relative protein levels in COS-7 cells 
co-transfected with the NRs and a retinoid luciferase-
reporter (Figure 1C). The ATRA-dependent decrease in 
RARα1, RARα2, and PML-RAR proteins is suppressed 
by MG132 (Figure 1D). As observed for RARα1 (Figure 
1D) and PML-RAR (data not shown) [24, 25], inhibition 
of RARα2 degradation by MG132 increases the induction 
of luciferase activity by ATRA.
Generation of NB4 derived cell populations 
stably and selectively silenced for PML-RAR, 
RARAα1 and RARα2
We designed shRNAs targeting the fusion site of 
PML-RAR as well as the A/B-regions of RARα1 and 
RARα2 (Supplementary Figure S2). The RARα1-targeting 
shRNAs recognize also RARα4 and are expected to 
silence it too. However, RARα4 is undetectable in NB4 
cells (data not shown) and it was not further considered. 
Following a preliminary screening based on transient 
transfection of COS-7 cells with PML-RAR, RARAα1 or 
RARα2 cDNAs, we selected one shRNA for each receptor 
and one shRNA recognizing all the receptors (ALLsh). 
ALLsh efficiently down-regulates RARα1, RARα2 and 
PML-RAR in COS-7 cells (Figure 2A). The RARα1, 
RARα2 and PML-RAR shRNAs (RA1sh, RA2sh and 
PMRsh) reduce the levels of the targets specifically, while 
the negative-control shRNA (SCRsh) retroviral construct 
and the void vector (VOID) exert no effect.
We isolated NB4 cell populations with stable 
integration of the selected negative-control (SCRsh-NB4), 
the RARα1 (RA1sh-NB4), the RARα2 (RA2sh-NB4) and 
the PML-RAR (PMRsh-NB4) shRNAs. Specific knock-
down of the targets is confirmed for RA1sh-NB4 and 
PMRsh-NB4 cells (Figure 2B), while the parental and 
SCRsh-NB4 counterparts express similar levels of RARα1 
and PML-RAR. The same amounts of PML proteins are 
evident in parental and PMRsh-NB4 cells supporting 
the specificity of the PML-RAR targeting shRNA 
(Supplementary Figure S3). Following WB (Figure 
2C-upper) or immuno-precipitation (Figure 2C-lower) 
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Figure 1: Expression, ATRA-dependent proteolytic degradation and transcriptional activity of PML-RAR, RARα2 
and RARα1. A. NB4 cells were treated with vehicle (DMSO) or ATRA (0.1 μM) for 48 hours. Total RNA was extracted and subjected 
to RT-PCR analysis using Taqman assays for the indicated mRNAs. The results are expressed as the mean+SD of 3 replicates. B. Upper: 
NB4 cells were treated with vehicle (DMSO) or ATRA (0.1 μM) for 40 hours before addition of the proteasome inhibitor, MG132 (40 μM) 
for 8 hours. Total protein extracts were subjected to Western blot analysis with an anti-RARα antibody [RP alpha (F)]. Actin was used 
as a loading control. Lower: NB4 cells were treated as above with vehicle (DMSO), ATRA (0.1 μM), the proteasome inhibitor, MG132 
(20 and 40 μM) or ATRA+MG132. Cell extracts were immuno-precipitated with an anti-RARα2 antibody [Ab25alpha2(A2)] coupled to 
protein G-sepharose beads (IP = immuno-precipitation) and the immuno-precipitates were subjected to Western blot analysis with the 
same anti-RARα antibody used in the Upper panel. Equivalent amounts of protein extracts were used to immuno-precipitate RARα2, 
as indicated by the levels of actin in the extracts before addition of the anti-RARα2 antibody (input). COS-7 = Total extracts of COS-7 
cells transfected with a pcDNA3-RARα2 plasmid. The calculated molecular weight (M.W.) of the indicated proteins is shown on the left. 
C. COS-7 cells were transfected with pcDNA3-RARα2, pcDNA3-RARα1 and pSG5-PML-RAR plasmids and the retinoid dependent 
Luciferase reporter, β2RARE-Luc. Sixteen hours following transfection, cells were treated with DMSO or the indicated concentrations of 
ATRA for an extra 24 hours. Cell extracts were used for the measurement of luciferase activity and the indicated proteins by Western blot 
analysis. Luciferase activity data are expressed as the mean+SD of two replicates. D. COS-7 cells were transfected as in (C). Sixteen hours 
following transfection, cells were treated with vehicle (DMSO) or ATRA (1 μM ) for 16 hours and vehicle or MG132 (40 μM) for an extra 
8 hours. Cell extracts were used for the measurement of luciferase activity and the indicated proteins by Western blot analysis. Luciferase 
activity data are expressed as the mean+SD of two replicates.
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Figure 2: PML-RAR, RARα2 and RARα1 knock-down in COS-7 and NB4 cells. A. COS-7 cells were transiently transfected 
with the pcDNA3, pcDNA3-RARα2, pcDNA3-RARα1 and pSG5-PML-RAR plasmids in the presence of the indicated shRNA-containing 
retroviral vectors and corresponding void vector (VOID). Sixteen hours following transfection, cell extracts were subjected to Western blot 
analysis using an anti-RARα antibody [RP alpha (F)]. Actin is used as a loading control. ALLsh = shRNA targeting RARα1 (RARα.v1 
and RARα.v3 mRNAs), RARα2 (RARα.v2 mRNA) and RARα4 (RARα.v4 mRNA); RA1sh = shRNA targeting RARα1; RA2sh = shRNA 
targeting RARα2; PMRsh = shRNA targeting PML-RAR; SCRsh = scramble shRNA (negative control). The (-) symbol represents extracts 
from COS-7 cell transfected in the absence of any shRNA. B. The indicated NB4 cell populations stably infected with shRNAs targeting 
PML-RAR (PMRsh-NB4), RARα1 (RA1sh-NB4), RARα2 (RA2sh-NB4) or scramble shRNA (SCRsh-NB4) as well parental NB4 cells 
(NB4) were grown under standard conditions for 48 hours. Cell extracts were subjected to Western blot analysis using the same anti-RARα 
antibody as in (A). Actin is used as a loading control. C. Upper (WB = Western Blots): Extracts from the indicated COS-7 cells transfected 
with RARα1 and RARα2 expressing plasmids as well as the indicated NB4 cells [see (B)], were subjected to Western blot analysis with 
anti-RARα2 [Ab25alpha2(A2)] and β-actin (loading control) antibodies. SCRsh-NB4 = cell treated with vehicle (DMSO) for 24 hours; 
SCRsh-NB4+ATRA = cell treated with ATRA (1 μM) for 24 hours. Kazumi cells extracts are used as a control for RARα2 expression, as 
they contain high levels of the protein. Lower (IP = immunoprecipitations): Extracts from the indicated NB4 cell populations and parental 
NB4 cells [see (B)], were immuno-precipitated with an anti-RARα2 antibody [Ab25alpha2(A2)] coupled to Protein G sepharose beads. 
The immuno-precipitates were subjected to Western blot analysis with a different anti-RARα antibody [RP alpha (F)]. Equivalent amounts 
of protein extracts were used to immuno-precipitate RARα2, as indicated by the levels of actin in the extracts before addition of the anti-
RARα2 antibody (input). D. Extracts from the indicated NB4 cell populations [see (B)] were immuno-precipitated with an anti-RARα1 
antibody [Ab10alpha1(A1)] or mouse immunoglobulin G (IgG) coupled to Protein G Sepharose beads or Protein G Sepharose beads alone 
(-). The immuno-precipitates were subjected to Western blot analysis with a different anti-RARα antibody [RP alpha (F)]. The actin loading 
control of the immuno-precipitation experiment is shown (input). The calculated molecular weight (M.W.) of each protein is indicated on 
the left of each blot.
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with the anti-RARα2 antibody [Ab25a(A2)], a remarkable 
and selective down-regulation of RARα2 is observed 
in RA2sh-NB4 cells. If similar immuno-precipitation 
experiments are performed with an anti-RARα1 antibody, 
a decrease in the amounts of RARα1 is evident in RA1sh-
NB4 relative to SCRsh-NB4 cells, confirming the WB 
results obtained on cellular extracts (Figure 2D).
PML-RAR and RARα2 silencing increases 
differentiation of NB4 cells in the absence or 
presence of ATRA, while RARα1 silencing exerts 
opposite effects in the presence of the retinoid
The consequences of RARα1, RARα2 and PML-
RAR knock-down on NB4 growth were evaluated in the 
absence/presence of ATRA (Figure 3A). In the absence 
of ATRA, RA1sh-NB4 and PMRsh-NB4 cells grow faster 
and more slowly, respectively, than SCRsh-NB4 blasts. 
No difference is observed between RA2sh-NB4 and 
SCRsh-NB4 cells. Both PML-RAR and RARα2 silencing 
enhances ATRA growth-inhibitory action, while RARα1 
knock-down exerts opposite effects.
Under basal conditions, a significant fraction of 
PMRsh-NB4 and RA2sh-NB4 cells show morphological 
signs of granulocytic maturation which are not observed 
in RA1sh-NB4 cells, such as nuclear lobulation, increased 
cytoplasmic/nuclear ratio and appearance of cytoplasmic 
granules/vesicles (Supplementary Figure S4). As expected, 
ATRA induces morphological features of granulocytic 
differentiation in the majority of SCRsh-NB4 cells. While 
similar features are observed in ATRA-treated PRsh-
NB4 and RA2sh-NB4 cells, differentiation is much less 
evident in RA1sh-NB4 cells. In the absence of ATRA, 
SCRsh-NB4 blasts show the same low levels of CD11b 
and CD11c myeloid differentiation markers [26] (Figure 
3B). Exposure to ATRA renders SCRsh-NB4 cells highly 
positive for the two markers and it increases CD11b as 
well as CD11c mean-associated-fluorescence (MAF). In 
RA1sh-NB4 cells, ATRA-dependent induction of these 
markers is suppressed, as indicated by CD11b-/CD11c-
positivity and MAF. Relative to SCRsh-NB4 cells, a 
substantial increase in CD11b-/CD11c-positivity is already 
observed in PMRsh-NB4 and RA2sh-NB4 blasts grown 
under basal conditions. The phenomenon is accompanied 
by enhanced MAF values after exposure to ATRA. Thus, 
RA2sh-NB4 and PMRsh-NB4 cells show similar patterns 
of basal and ATRA-dependent CD11b/CD11c expression. 
We also defined the action of RARAα1, RARα2 and PML-
RAR shRNAs on 3 transcription factors controlling APL 
blast granulocytic maturation, i.e. PU.1 [27, 28], cEBPβ 
[29, 30] and STAT1α [31] (Figure 3C). RARAα1 knock-
down reduces the induction of PU.1, cEBPβ and STAT1α 
observed in ATRA-exposed parental and SCRsh-NB4 blasts. 
In contrast, PMRsh-NB4 and RA2sh-NB4 cells show higher 
basal levels of STAT1α and cEBPβ as well as enhanced 
induction of PU.1, STAT1α and cEBPβ by ATRA.
To evaluate the effects of PML-RAR, RARα2 and 
RARAα1 silencing on direct retinoid-targets, we focused 
on CD38 (Figure 3B) and paxillin (PXN) (Figure 3C) 
which are up-regulated by ATRA in NB4 and other cell 
types [32–35]. Over 90% of all shRNA-infected cells 
are CD38+. ATRA increases CD38-MAF in SCRsh-
NB4 and RA1sh-NB4 cells. The ATRA-dependent effect 
is considerably enhanced in PMRsh-NB4 and RA2sh-
NB4 blasts. This enhancement is not evident in RA1sh-
NB4 cells, which show a slight reduction of the ATRA-
dependent CD38-MAF increase in SCRsh-NB4 blasts. 
Similar expression patterns are observed in the case 
of PXN. Thus, RARα2 and PML-RAR are negative 
determinants of myeloid differentiation and they down-
regulate direct retinoid-responsive genes.
To evaluate whether the negative action of 
RARα2 on myeloid differentiation is specific to APL 
and dependent on PML-RAR expression, we performed 
studies in the PML-RAR- and ATRA-sensitive HL-
60 model [45, 46]. In HL-60 cells, RARα-v3 is most 
abundant followed by RARα-v1 and RARα-v2 mRNAs, 
while negligible amounts of RARα-v4 are measured 
(Supplementary Figure S5A). ATRA up-regulates 
RARα-v2 and RARα-v3 mRNAs. Relative to control 
HL-60 populations (SCRsh-HL60 and Void-HL60 cells), 
RARα2 knock-down (RA2sh-HL60) (Supplementary 
Figure S5B) reduces basal cell-growth and enhances 
ATRA anti-proliferative action (Supplementary Figure 
S5C). In basal conditions, RARα2 knock-down increases 
the number of CD11b+ RA2sh-HL60 cells (Supplementary 
Figure S5D). Following ATRA exposure (0.1 and 1.0 
μM), the number of CD11b+ cells and CD11b-MAF 
values are higher in RA2sh-HL60 than SCRsh-HL60 or 
Void-HL60 cells. Both ATRA concentrations enhance 
CD11c-MAF induction in RA2sh-HL60 relative to control 
cells. Finally, ATRA-dependent up-regulation of STAT1α, 
cEBPβ and PU.1 are enhanced by RARα2 knock-down 
(Supplementary Figure S5E). As for the consequences 
of RARα2 knock-down on the direct retinoid-responsive 
genes, all RA2sh-HL60 cells are CD38+, while SCRsh-
HL60 and Void-HL60 blasts are CD38- (Supplementary 
Figure S5F). As expected, ATRA renders SCRsh-HL60 
and Void-HL60 cells CD38+ and increases CD38-MAF in 
SCRsh-HL60, Void-HL60 and RA2sh-HL60 to the same 
extent. RARα2 knock-down stimulates ATRA-dependent 
induction of paxillin (Supplementary Figure S5E) as 
well as c-EBPε and CYP-26A1 mRNAs (Supplementary 
Figure S5G). All this confirms and extends the NB4 data, 
indicating that RARα2 exerts a negative action on myeloid 
maturation independently of PML-RAR expression.
RARα2 over-expression reduces ATRA-
dependent differentiation of NB4 cells
To support the unexpected data obtained following 
RARα2 silencing in NB4 cells, we took a specular 
approach and stably over-expressed the retinoid receptor 
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Figure 3: Effects of PML-RAR, RARα2 and RARα1 knock-down on the growth and differentiation of NB4 cells. 
A. The indicated NB4 cell populations stably infected with shRNAs targeting PML-RAR (PMRsh-NB4), RARα1 (RA1sh-NB4), RARα2 
(RA2sh-NB4) or the control scramble shRNA (SCRsh-NB4) were grown in the presence of vehicle (DMSO) or ATRA (1 μM) for the 
indicated amount of time. The number of viable cells determined after staining with trypan blue is indicated. Each point is the mean+S.D. 
of three replicate cultures. ** = Significantly different relative to the corresponding SCRsh-NB4 time point (p<0.01 after Student’s t-test); 
* = Significantly different relative to the corresponding SCRsh-NB4 time point (p<0.05 after Student’s t-test). B. The indicated NB4 
cell populations [see (A)] were grown in the presence of vehicle (DMSO) or ATRA (1 μM) for 72 hours. Cells were subjected to FACS 
analysis for the indicated markers. The column graphs on the left indicate the percentage of CD11b-, CD11c- and CD38-positive cells. The 
graphs on the right indicate the MAF (mean-associated-fluorescence) values determined. The results are representative of two independent 
experiments. C. The indicated NB4 cell populations were treated as in (B) for 48 hours. Cell extracts were subjected to Western blot analysis 
for the indicated proteins. Actin is used as a loading control. The results shown in the upper and lower panels were obtained in separate 
experiments. Each line shows cropped lanes of the same gel, hence the results can be compared across the lanes, as they were obtained with 
the same exposure time. The calculated molecular weight (M.W.) of each protein is indicated on the left. The results are representative of 
at least two independent experiments.
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in the same cellular context. To this purpose, we produced 
NB4 cell populations stably transfected with a RARα2 
plasmid (pCDH-RA2) or the void vector (pCDH) (Figure 
4A). Independent control (pCDH-NB4a; pCDH-NB4b) 
and RARα2 over-expressing (pRA2-NB4a; pRA2-NB4b) 
cell populations were compared for their growth in the 
absence/presence of ATRA. In pCDH-NB4a, pRA2-
NB4a and pRA2-NB4b, the basal growth and the anti-
proliferative action of ATRA are similar (Figure 4B). In 
untreated parental, pCDH-NB4 and pRA2-NB4 cells, the 
same low levels of CD11b- and CD11c-MAF are observed 
(Figure 4C). However, the ATRA-dependent increase of 
CD11b-MAF in parental, pCDH-NB4a and pCDH-NB4b 
cells is suppressed in pRA2-NB4a and pRA2-NB4b cells. 
RARα2 over-expressing blasts show also a substantial 
inhibition of ATRA-dependent CD11c induction. In 
vehicle and ATRA-treated pRA2-NB4a, pRA2-NB4b 
and pCDH-NB4a cells, a similar trend is evident, if we 
compare the levels of PU.1, cEBPβ and paxillin, (Figure 
4D). Hence, RARα2 over-expression and RARα2 knock-
down exert opposite effects on the myeloid-associated 
markers considered.
Silencing of PML-RAR and RARα2 exerts 
similar effects on the NB4 whole-genome  
gene-expression profiles
We compared the gene-expression profiles of 
PMRsh-NB4, RA2sh-NB4, RA1sh-NB4 and SCRsh-NB4 
cells exposed to vehicle or ATRA for 48 hours [36, 37]. 
The time point was selected because it precedes terminal 
differentiation of NB4 cells and it is characterized by large 
and ATRA-dependent variations of the whole-genome 
gene-expression profiles in parental NB4 cells. We 
identified 5,567 genes whose expression is significantly 
modified in at least one of the comparisons considered 
(p<0.05, BH, 0.6 fold-change threshold). Differentially 
expressed genes can be classified into 8 clusters according 
to their expression pattern by the K-means algorithm 
(Supplementary Table S1). Cluster-1 and Cluster-2 genes 
are up- or down-regulated in PMRsh-NB4 cells under 
basal conditions and ATRA exerts no or very limited 
effects on their expression (Figure 5). In PMRsh-NB4 
cells, up-/down-regulation of the majority of genes 
reaches statistical significance. Although changes are 
smaller and often lack significance, the same regulation 
pattern of Clusters-1/-2 genes is observed in RA2sh-NB4 
cells. Cluster-3/-4 genes are up-regulated by ATRA in 
SCRsh-NB4 and RA1sh-NB4 cells to the same extent. 
ATRA-dependent up-regulation of Cluster-3 genes is 
enhanced in PMRsh-NB4 and RA2sh-NB4 cells, while 
down-regulation of Cluster-4 genes is repressed following 
PML-RAR and RARα2 knock-down (Figure 5). The 
differences reach statistical significance in a considerable 
fraction of genes. Once again, PML-RAR and RARα2 act 
on common gene-sets which are regulated by these NRs 
in the same direction. Clusters-5/-7 consist of numerous 
genes whose basal or ATRA-dependent expression is left 
generally unaffected by PML-RAR, RARα1 or RARα2 
knock-down (Figure 6). Cluster-5 genes are up-regulated, 
while Cluster-7 genes are down-regulated by ATRA. 
Following ATRA treatment, Clusters-6/-8 have similar 
profiles of expression relative to Clusters-5/-7. However, 
Clusters-6/-8 genes are up-/down-regulated by PML-RAR 
and RARα2 knock-down also in basal conditions. Overall, 
the effects of RARα1 knock-down are small with few 
genes showing statistically significant alterations in their 
expression. However, a general trend towards inhibition 
of the ATRA-dependent effects, with particular reference 
to Clusters-3/-5/-7, is observed in RA1sh-NB4 cells. This 
may be partially explained by incomplete silencing of 
RARα1 (see Figure 2A-2B).
We performed pathway enrichment analysis of the 
genes significantly regulated in PMRsh-NB4 (comparisons 
c and g/d) and RA2sh-NB4 cells (comparisons b and f/d) 
using annotated gene-collections (Molecular Signatures 
database) (Supplementary Table S2). In the 3 gene-
collections considered, we found a significant overlap 
between the gene-sets enriched in PMRsh-NB4 and 
RA2sh-NB4 cells (Supplementary Figure S6A). Many of 
the genes regulated in PMRsh-NB4 and RA2sh-NB4 cells 
are direct PML-RAR targets [19] (Supplementary Figure 
S6B). The significant overlap between genes regulated 
by PML-RAR or RARα2 silencing and those regulated 
in NPM1-mutated blasts [38] (Supplementary Figure S7) 
may be of relevance for ATRA therapeutic action, since 
AMLs characterized by NPM1-mutations are deemed to be 
ATRA-sensitive [39–41]. Finally, enrichment in the genes 
of the GO “Immune-System-Process” (Supplementary 
Figure S8) may be linked to the neutrophil differentiation 
program triggered by PML-RAR and RARα2 knock-
down. Indeed, emergency granulopoiesis is stimulated by 
inflammatory cytokines [42, 43], [44]. 
Finally, we evaluated the expression pattern of 
the genes contained in the “hematopoietic-cell-lineage” 
KEGG pathway (hsa04640) (Supplementary Figure S9), 
which is significantly enriched in genes regulated by 
PML-RAR (p<1E-6) and RARα2 (p<3.38E-4) silencing. 
As expected, the gene-regulation pattern observed 
following challenge with ATRA is consistent with myeloid 
differentiation. For instance, ATRA down-regulates 
CD135 (FLT3), a marker of hematopoietic stem-cells, 
while it up-regulates the neutrophil/monocyte marker, 
CD11b (ITGAM). Many ATRA-regulated mRNAs are 
also modulated by PML-RAR and RARα2 knock-down 
in the same direction.
RARα2 interferes with the transcriptional 
activity of RARα1 and PML-RAR
To evaluate whether RARα2 inhibitory action on 
myeloid differentiation involves direct effects on RARα1 
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Figure 4: Effects of RARα2 over-expression on the growth and differentiation of NB4 cells. NB4 cells were transfected with 
the pCDH-RA2 plasmid and the corresponding void vector, pCDH. Two distinct RARα2 expressing (pRA2-NB4a and pRA2-NB4b) and two 
(pCDH-NB4a and pCDH-NB4b) cell populations were isolated. A. Cells were treated with ATRA (1 μM) for 24 hours. Cell extracts were 
immuno-precipitated with an anti-RARα2 antibody [Ab25alpha2(A2)] coupled to Protein G sepharose beads. The immuno-precipitates 
were subjected to Western blot analysis with a different anti-RARα antibody [RP alpha (F)]. Equivalent amounts of protein extracts 
were used to immuno-precipitate RARα2, as indicated by the levels of actin present in the extracts before addition of the anti-RARα2 
antibody (input). B. Cells were treated with vehicle (DMSO) or ATRA (1 μM) for the indicated amount of time. The number of viable cells 
determined after staining with trypan blue is indicated. Each point is the mean+S.D. of three replicate cultures. C. Cells were grown in the 
presence of vehicle (DMSO) or ATRA (1 μM) for 72 hours and subjected to FACS analysis for the determination of CD11b and CD11c. The 
column graphs indicate the MAF (mean-associated-fluorescence) values determined. D. Cells were grown as in (C) and treated with vehicle 
(DMSO) or ATRA (1 μM) for 48 hours. Cell extracts were subjected to Western blot analysis for the indicated proteins. Actin is used as a 
loading control. The calculated molecular weight (M.W.) of each protein is indicated on the left.
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Figure 5: Perturbations of the basal and ATRA-dependent gene expression caused by PML-RAR, RARα2 and RARα1 
knock-down in NB4 cells. Classification by K-means clustering: Cluster-1 through Cluster-4 genes. The indicated NB4 cell populations 
stably infected with PML-RAR (PMRsh-NB4), RARα1 (RA1sh-NB4), RARα2 (RA2sh-NB4) and scramble (SCRsh-NB4) shRNAs were 
grown in the presence of vehicle (DMSO) or ATRA (0.1 μM) for 48 hours. Total RNA was used to perform whole-genome gene-expression 
microarray experiments. For each experimental group, data are reported as the log2 of the ratio vs basal expression in SCRsh-NB4 cells 
(SCRsh_DMSO). The genes regulated in at least one of the experimental conditions are grouped into eight Clusters and the figure illustrates 
Cluster-1 to Cluster-4. The upper graphs are heat-maps generated by hierarchical clustering using Pearson’s distances. The statistical 
significance of the indicated comparisons (CONTRASTS, p<0.05, log2 ratio > 0.6 or < -0.6) is shown on the right by the blue lines. The 
lower line graphs show the global expression profiles.
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Figure 6: Perturbations of the basal and ATRA-dependent gene expression caused by PML-RAR, RARα2 and RARα1 
knock-down in NB4 cells. Classification by K-means clustering: Cluster-5 through Cluster-8 genes. The indicated NB4 cell populations 
stably infected with PML-RAR (PMRsh-NB4), RARα1 (RA1sh-NB4), RARα2 (RA2sh-NB4) and scramble (SCRsh-NB4) shRNAs were grown 
in the presence of vehicle (DMSO) or ATRA (0.1 μM) for 48 hours. Total RNA was used to perform whole-genome gene-expression microarray 
experiments. For each experimental group, data are reported as the log2 of the ratio vs basal expression in SCRsh-NB4 cells (SCRsh_DMSO). The 
genes regulated in at least one of the experimental conditions are grouped into eight Clusters and the figure illustrates Cluster-5 to Cluster-8. The 
upper graphs are heat-maps generated by hierarchical clustering using Pearson’s distances. The statistical significance of the indicated comparisons 
(CONTRASTS, p<0.05, log2 ratio > 0.6 or < -0.6) is shown on the right by the blue lines. The lower line graphs show the global expression profiles.
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and PML-RAR transcriptional activity, we used a co-
transfection approach in COS-7 cells, a popular model 
characterized by no expression of PML-RAR or RARα2 and 
very low expression of RARα1 [17, 23, 26]. We performed 
co-transfection studies with RARα2 and RARα1 or PML-
RAR in COS-7 cells transiently expressing the β2RARE-tk-
Luc reporter. Separate transfection of RARα1, PML-RAR 
or RARα2 stimulates ATRA-dependent luciferase activity 
(Figure 7A). Simultaneous over-expression of RARα2 and 
RARα1 or PML-RAR reduces this stimulation, indicating 
cross-interference. Cross-interference is not due to effects 
on the amounts of RARα2, RARα1 or PML-RAR measured 
following separate and combined transfection in COS-7 
cells exposed to vehicle or ATRA (Figure 7B). Cross-
interference is specific to RARα2 and RARα1 or PML-
RAR, as indicated by the results obtained with RARβ2 or 
RARγ2. Indeed, co-transfection with RARα2 increases or 
leaves unaffected luciferase activity as compared to separate 
RARα2, RARβ2 or RARγ2 transfection (Figure 7C).
RARα2 binds to RARα1 and PML-
RAR directly: insights into the structural 
determinants of these interactions
To establish whether cross-interference involve 
interactions between RARα2, RARα1 and/or PML-
RAR, we performed pull-down experiments in COS-7 
cells transfected with RARα1. Vehicle and ATRA-treated 
COS-7 extracts were incubated with glutathione-S-
transferase(GST)-tagged RARα2 (GST-RARα2) or 
control GST (Figure 8A). Upon WB of the GST-RARα2 
pull-down fraction with an anti-RARα antibody, a band 
corresponding to transfected RARα1 is visible regardless 
of ATRA treatment. A similar band is not detected after 
GST pull-down. Superimposable results are observed 
if RARα1 is substituted by PML-RAR (data not show). 
Specular pull-down studies with GST-RARα1 and GST-
RARα1DEF (a RARα1 recombinant product consisting of 
the entire D/E/F) on extracts of COS-7 cells transfected 
with pHA-RARα2, pHA-SNAIL and pHA confirm and 
extend the results (Figure 8B and Supplementary Figure 
S10A). In fact, the data obtained following WB with anti-
HA antibodies indicate that RARα2 is pulled-down by 
both GST-RARα1 and GST-RARα1DEF. ATRA does not 
affect this interaction. Similar experiments conducted with 
GST-RARα1ABC do not result in RARα2 pull-down (data 
not shown). The specificity of the interaction between 
RARα2 and the D/E/F regions of RARα1 is supported 
by the results obtained in COS-7 cells transfected with 
the negative pHA-SNAIL and the positive pSG5-RXRα 
controls (Supplementary Figure S10B).
Far-Western experiments were performed 
(Figure 8C) on extracts of COS-7 cells transfected with 
hemoagglutinin(HA)-tagged RARα2 and treated with 
vehicle or ATRA. Immobilized HA-RARα2 immuno-
precipitates (anti-HA antibodies) were challenged 
with GST-RARα1. Following incubation with GST-
RARα1, but not GST, an anti-GST antibody highlights 
a band at the height of HA-RARα2. This demonstrates 
a direct interaction between HA-RARα2 and GST-
RARα1, which is reproduced with the 2 GST-RARα1 
derivatives consisting of the DEF regions containing 
(GST-RARα1DEF) or lacking the H12 helix [GST-
RARα1DEFD(408-416)]. The GST-RARα1 protein 
consisting of the ABC regions (GST-RARα1ABC) does not 
interact with HA-RARα2. No quantitative difference in 
the RARα2/RARα1 interaction is observed in the absence/
presence of ATRA.
To confirm the results obtained, we performed 
co-immuno-precipitation experiments in COS-7 cells 
transfected with RARα2 alone or in combination with 
RARα1 using the specific anti-RARα2 antibodies. This was 
followed by WB with the distinct antibody [RPalpha(F)] 
detecting both RARα2 and RARα1. Co-precipitation 
of RARα1 (Figure 8D) is observed only in cells co-
transfected with RARα2. The amounts of co-precipitated 
RARα1 are not influenced by ATRA treatment. RARα2 is 
immuno-precipitated only from cells transfected with the 
corresponding construct, confirming the specificity of the 
anti-RARα2 antibody. To get insights into the structural 
determinants of RARα2/RARα1 direct interaction, we 
performed similar co-immuno-precipitation experiments 
in COS-7 cells co-transfected with RARα2 and selected 
RARα1 mutants of critical residues in the D/E/F regions 
(Figure 8E). Co-precipitation of RARα2 is observed in 
cells co-transfected with wild-type RARα1, the RARα1-
S157A mutant (affecting a phosphorylation site at the C/D 
regions interface) and RARα1-I396E mutant (influencing 
the interactions with co-activators) [47]. In contrast, the 
RARα1-S369A mutant affecting the protein-kinase-A, 
mitogen-and-stress-activated-protein-kinase and p38-
kinase phosphorylation site [23, 32, 48] does not interact 
with RARα2. The amounts of co-precipitated RARα1 
and derived mutants are not significantly influenced by 
ATRA. Similar immuno-precipitation studies performed 
after co-transfection of RARα2, wild-type PML-RAR and 
the PML-RAR-S873A (corresponding to RARα1-S369A) 
confirm the above results. In fact, RARα2 co-immuno-
precipitates only with wild-type PML-RAR (Figure 8F).
To evaluate whether interactions between RARα2 
and RARα1 or PML-RAR are also observed in the native 
APL context, we performed further immuno-precipitation 
studies in our NB4 models. RARα2 is immuno-precipitated 
in extracts from parental, SCRsh-NB4, RA1sh-NB4 and 
PMRsh-NB4 but not in RA2sh-NB4 cells. An extra 52 
kDa band is detectable in the immuno-precipitates of 
untreated NB4, SCRsh-NB4 and PMRsh-NB4 only upon 
long exposures and its intensity is dramatically increased 
by ATRA (Figure 9A). The band corresponds to RARα1, 
as it is absent in RA1sh-NB4 cells. To evaluate whether 
RARα2 is capable of interacting with PML-RAR, WB 
experiments on the anti-RARα2 immuno-precipitates were 
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Figure 7: Interference between RARα2 and RARα1 or PML-RAR transcriptional activity. A. COS-7 cells were transfected with 
pcDNA3-RARα2, pcDNA3-RARα1 and pSG5-PML-RAR plasmids alone or in combination and β2RARE-Luc. Sixteen hours following transfection, 
cells were treated with DMSO or ATRA (1 μM) for 24 hours. B. COS-7 cell extracts were subjected to Western blot analysis with an anti-RARα 
antibody [RP alpha (F)]. The same amounts of extracts used for the determination of RARα1 and RARα2 were subjected to Western blot analysis 
to determine the loading control, β-actin. C. COS-7 cells were transfected with pcDNA3-RARα2, pcDNA3-RARα1, pSG5-RARβ2 and pSG5-RARg2 
plasmids alone or in combination and β2RARE-Luc. Sixteen hours following transfection, cells were treated with DMSO or ATRA (1 μM) for a further 
24 hours. Luciferase activity is expressed as the ratio of ATRA/DMSO luciferase activity (fold-change). Each value is the mean+SD of two replicates.
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conducted with the antibody detecting PML-RAR, RARα2 
and RARα1 (Figure 9B). In untreated SCRsh-NB4 and 
RA1sh-NB4 cells, PML-RAR and RARα2 co-immuno-
precipitate. In the same cells treated with ATRA, the 
amounts of co-immuno-precipitated PML-RAR increase. 
The co-immuno-precipitated PML-RAR band is observed 
in neither untreated nor ATRA treated RA2sh-NB4 and 
PMRsh-NB4 cells.
Figure 8: Functional and physical interactions between RARα2 and RARα1 or PML-RAR. A. GST pull-down: the GST-tagged 
recombinant protein, GST-RARα2 and GST were used. The two recombinant proteins conjugated to Glutathione-Sepharose beads were incubated 
with extracts of COS-7 cells transfected with pcDNA3-RARα1 and treated with vehicle or ATRA (1 μM) for 4 hours. GST pull-down precipitates 
were blotted on nitro-cellulose filters, hybridized with an anti-RARα [RP alpha (F)] (left panel) and subsequently with an anti-GST antibody (right 
panel). The blot was not stripped between the two hybridizations. Input: cell extracts (10 μg of protein) representing 10% of the total amount of 
protein were subjected to Western blot analysis with the above anti-RARα antibody. B. GST pull-down: the GST-tagged recombinant proteins, 
GST-RARα1 and GST-RARα1DEF were used. The two recombinant proteins conjugated to Glutathione-Sepharose beads were incubated with 
extracts of COS-7 cells transfected with pHA-RARα2 as well as the negative controls, pHA-SNAIL plasmid and pcDNA3 plasmid containing the 
HA tag (pHA). Transfected cells were treated with vehicle or ATRA as in (A). As an internal control of the experiment, we performed a pull-down 
assay with the GST protein coupled to Glutathione-Sepharose beads on extracts of cells transfected with pHA-RARα2. GST pull-down precipitates 
were subjected to Western blot analysis with anti-HA (upper panels) and anti-GST antibodies (lower panels). C. Far-Western: COS-7 cells were 
transfected with a pcDNA3 plasmid containing a haemoagglutinin (HA) tagged RARa2 cDNA (pHA-RARα2). Cell extracts were precipitated 
with agarose beads conjugated with an anti-HA monoclonal antibody. The immuno-precipitates were subjected to Far-Western analysis using 
the following GST-tagged RARα1 recombinant proteins: GST-RARα1 = full-length RARα1; GST-RARα1ABC = RARα1 ABC regions; GST-
RARα1DEF = RARα1 DEF regions; GST-RARα1DEFD(408-416) = RARα1 DEF regions lacking the H12 helix. Input: cell extracts (10 μg of 
protein) representing 10% of the total amount of protein used for the immune-precipitations were subjected to Western blot analysis with an 
anti-HA antibody. Each line shows cropped lanes of the same gel, hence the results can be compared across the lanes, as they were obtained 
with the same exposure time. D. Immunoprecipitations (IP): COS-7 cells were transfected with pcDNA3-RARα1 and pcDNA3-RARα2 alone or 
in combination. Sixteen hours following transfection, cells were treated with vehicle or ATRA (1 μM) for 4 hours. The indicated extracts were 
immuno-precipitated with anti-RARα2 antibodies and subjected to Western blot analysis with a different anti-RARα antibody [RP alpha (F)]. 
The two leftmost lanes represent controls of RARα1 transfected cells directly submitted to Western blot analysis without immuno-precipitation. 
Equivalent amounts of protein extracts were used to immuno-precipitate RARα2, as indicated by the levels of RARα2 [Ab25alpha2(A2) antibody] 
and RARα1 [Ab10alpha1(A1)antibody]in the extracts (input). Each line shows cropped lanes of the same gel, hence the results can be compared 
across the lanes, as they were obtained with the same exposure time. (Continued)
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In conclusion, our data demonstrate that RARα2 
is capable of binding to RARα1 and PML-RAR and this 
binding may be at the basis of the observed functional 
interferences. The binding interface is located in the D/E/F 
region of RARα1 where the Ser-369 phosphorylation site 
plays a pivotal role in RARα2/RARα1 interaction. Binding 
of RARα2 to RARα1 and functional inhibition of the latter 
receptor may also partially explain the similarity in the 
effects afforded by RARα2 and PML-RAR silencing in 
NB4 cells.
DISCUSSION
It is believed that ATRA therapeutic action in 
APL involves degradation of PML-RAR [7, 49], which 
releases the suppressive effect exerted by the fusion 
protein on the product of the intact RARA allele, RARα 
[2, 3]. However, the existence of 3 RARα isoforms 
(RARα1, RARα2 and RARα4) adds complexity to 
the system. In the APL-derived NB4 cellular model, 
RARα2 and PML-RAR are negative regulators of 
the granulocytic differentiation program and act via 
common transcriptional mechanisms. The similarities 
between RARα2 and PML-RAR activities are observed 
not only in NB4 blasts under basal conditions, but 
also upon exposure to ATRA. Indeed, RARα2 and 
PML-RAR knock-down enhances ATRA-dependent 
induction of myeloid markers and the expression of 
direct retinoid target-genes. By converse, RARα1 
knock-down does not alter the basal differentiation 
state and gene-expression pattern of NB4 blasts, while 
it attenuates the ATRA-dependent induction of myeloid 
markers and the transcriptomic effects triggered by the 
retinoid. In NB4 cells, the negative effects of RARα2 
on ATRA differentiating activity are confirmed by 
over-expression approaches. As RARα2 is a negative 
prognostic factor in multiple myeloma [50, 51], the 
oncogenic action of RARα2 may extend to other 
hematological malignancies and solid tumors. With 
respect to this, we have preliminary evidence that over-
expression of RARα2 in a retinoid-responsive breast-
cancer cell line inhibits ATRA-simulated activity of 
a RARE-containing reporter and suppresses ATRA-
dependent induction of the retinoid targets, SMAD3 and 
β-catenin [52, 53].
Our gene-expression studies provide insights 
into the molecular mechanisms underlying RARα2 and 
PML-RAR involvement in the process of granulocytic 
maturation induced by ATRA in APL blasts. In 
physiological conditions, the process is constitutively 
Figure 8: (Continued) Functional and physical interactions between RARα2 and RARα1 or PML-RAR. E. Immuno-precipitation 
(IP): COS-7 cells were co-transfected with wild-type (WT) RARα2 or WT RARα1 and RARα1 mutants and subjected to immune-precipitation 
and Western blot analysis as in (D). F. Immuno-precipitation (IP): COS-7 cells were co-transfected with wild-type (WT) RARα2 or WT PML-
RAR and derived mutant. The extracts of transfected cells were treated and subjected to co-immuno-precipitation studies as in (D and E). Lanes 
5,6, 11 and 12 represent controls of PML-RAR and PML-RAR-S873A transfected cells directly submitted to Western blot analysis without 
immuno-precipitation.
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active during steady-state granulopoiesis, which is 
regulated by G-CSF, and GM-CSF [54, 55], and it is 
episodically stimulated during stress granulopoiesis, 
which is part of the innate immune response to 
infection/inflammation. Steady-state granulopoiesis 
requires the PU.1 and C-EBPα transcription factors 
[56–58], while stress granulopoiesis is stimulated by 
inflammatory cytokines like interferon [42, 43], IL-6, 
IL-3 and IL-1 [44]. ATRA seems to induce NB4 cell 
differentiation via activation of both steady-state and 
stress granulopoiesis, since it induces PU.1, cEBPβ 
and IL-1. As for steady-state granulopoiesis, ATRA-
dependent PU.1 induction is enhanced by PML-RAR 
and RARα2 knock-down, while it is blocked by RARα2 
over-expression. By converse, cEBPα is down-regulated 
by ATRA and this is consistent with the absence of GM-
CSF induction [59]. As for stress granulopiesis, PML-
RAR and RARα2 knock-down up-regulates the basal 
expression and enhances ATRA dependent induction of 
numerous inflammatory genes with particular reference 
to those involved in the interferon pathway, including 
STAT1 (Supplementary Table S1). Constitutive and 
ATRA-induced c/EBPβ protein as well as IL-1β mRNA 
levels are enhanced by PML-RAR and RARα2 knock-
down. Consistent with this, over-expression of RARα2 
down-regulates both basal and ATRA-dependent 
expression of c/EBPβ.
Given the similarity of the effects induced by 
RARα2 and PML-RAR knock-down, the two receptors 
may act via common mediators or interact functionally. 
Functional studies confirm that RARα2, PML-RAR and 
RARα1 activate the same RARE-containing reporter in an 
ATRA-dependent fashion. Unexpectedly, however, RARα2 
and PML-RAR interfere with RARα1 in terms of ligand-
dependent transcriptional activity. This may explain the 
similarities between RARα2 and PML-RAR in terms of NB4 
differentiation and gene-expression profiles. The observed 
functional interferences support the concept that RARα1 is 
indeed a potential target of RARα2 and PML-RAR activity 
in APL cells. The significance of this is sustained by the 
data obtained on direct retinoid targets, like CD38 (Figure 
3) CYP26A1 and RARβ (Supplementary Figure S11) in 
NB4 cells. Indeed, time- and ATRA-dependent induction of 
CYP26A1 and RARβ mRNAs is blocked by RARα1 and 
enhanced by RARα2 or PML-RAR knock-down. Functional 
antagonism is at least partially explained by the ability of 
RARα2 and PML-RAR to physically interact with each other 
and RARα1. With the exception of the immuno-precipitation 
assays performed in NB4 cells, our results demonstrate that 
direct binding is already observed in the absence of ATRA 
and it is not affected by the retinoid. However, in the NB4 
model, the levels of the RARα2/RARα1, PML-RAR/
RARα1 and RARα2/PML-RAR complexes are increased by 
ATRA. The increase may be ascribed to RARα2 and PML-
RAR induction by the retinoid (Figure 1). The interaction 
between RARα2 and RARα1 occurs also in PML-RAR-
negative HL-60 cells (Supplementary Figure S5B). Direct 
binding between the RARα2 and RARα1 or PML-RAR 
Figure 9: Physical interactions between RARα2 and RARα1 or PML-RAR in NB4 cells. A. and B. Immuno-precipitation 
(IP) experiments: SCRsh-NB4, RA1sh-NB4, PMRsh-NB4, RA2sh-NB4 and NB4 parental cells were treated with vehicle or ATRA (1 μM) 
for 4 hours. Cell extracts were immuno-precipitated using an anti-RARα2 antibody [Ab25alpha2(A2)]. This was followed by Western blot 
analysis of the immunoprecipitates with two distinct antibodies, which, in our experimental conditions, detect RARα2 and RARα1 (SC551) 
(A) or RARα2, RARα1 and PML-RAR [RP alpha (F)] (B), respectively. Input: cell extracts (10 μg of protein) representing 10% of the total 
amount of protein used for the immune-precipitations were subjected to Western blot analysis with an anti-actin antibody.
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involves the D/E/F regions. At present the binding interface 
is incompletely defined, although our data indicate that 
binding is influenced by phosphorylation of RARα1 Ser-369 
and the corresponding Ser-873 residue of PML-RAR. The 
observation is of particular interest for the therapeutic use 
of ATRA as it may suggest rational combination strategies 
aimed at enhancing the anti-leukemic potential of the 
retinoid. In fact, RARα1 S369 is a target phosphorylation site 
of protein-kinase-A, mitogen-and-stress-activated-protein-
kinase and p38-kinase [23, 32, 48]. From a therapeutic 
prospective, the action of combinations between ATRA 
and inhibitors of the three kinases should be specifically 
evaluated in appropriate pre-clinical models. With respect 
to this, it is noticeable that a p38-kinase inhibitor has been 
shown to boost the differentiating activity of ATRA in APL 
cells [32]. Thus, it would be tempting to speculate that at 
least part of the effect exerted by the p38-kinase inhibitor 
is related to suppression of the RARα2/RARα1 or RARα2/
PML-RAR interactions. In conclusion, we propose that the 
RARα2/RARα1 and RARα2/PML-RAR heterodimers may 
be transcriptionally inactive and may explain at least part of 
the observed functional antagonisms.
MATERIALS AND METHODS
Reagents and constructs
MG132, and ATRA were from Calbiochem and 
Sigma. Custom-designed short hairpin RNAs (shRNAs) 
were purchased from Ambion (Supplementary Figure 
S2). The 5′- and 3′-end of each hairpin RNA contain an 
EcoRI and a BamHI site to allow oriented cloning into 
the (pGreenPuro, System Biosciences, Palo Alto, CA) 
retroviral vector. The cDNA of the RARα2 coding region, 
which was amplified from NB4 cells, was cloned into 
the pCDNA3 plasmid (Invitrogen) and transferred to the 
pCDH-CMV lentivirus vector (System Biosciences), 
utilizing the EcoRI-NotI sites.
Cells and infection/transfection procedures
NB4 [60], HL-60 [61] and COS-7 cells were 
cultured as described [36, 62, 63]. We generated NB4 
cell populations silenced for PML-RAR and the RARα 
isoforms infecting cells with the SCRsh, PMRsh, RA1sh 
and RA2sh retroviral vectors according to standard 
protocols (System Biosciences). Following infection, 
NB4 cells were selected in RPMI medium containing 
10% bovine serum and puromycin (1.0 μg/ml) for at least 
15 days. Only NB4 cell populations characterized by 
>95% positivity to GFP following FACS analysis were 
considered. Subsequent passages of the cell populations 
were performed in complete RPMI medium containing 
puromycin (0.5 μg/ml). To isolate NB4 populations over-
expressing RARα2, cells were electroporated with pCDH-
CMV lentiviral vectors (System Biosciences) containing 
RARα2 (pRA2) using Neon Transfection (Invitrogen, Life 
Technologies). HL-60 cells were infected as above with 
the RA2sh, SCRsh or the void (Void) retroviral vector.
Gene expression microarrays and real-time 
reverse-transcription-PCR
The SCRsh-NB4, RA1sh-NB4, RA2sh-NB4 and 
PMRsh-NB4 cell populations were treated with (DMSO) 
or ATRA (0.1 μM ) for 48 hours. Total RNA was reverse 
transcribed, labeled and hybridized to whole-genome 
gene expression microarrays (G4851B, Agilent, Santa 
Clara, CA) as already described [22]. Fluorescent signals 
were quantified with a laser scanner (Agilent). The 
microarray raw data were deposited in the Arrayexpress 
database (The accession No. E-MTAB-4713). Real-time 
reverse-transcription-PCR (RT-PCR) was performed with 
Taqman gene expression assays (C/EBPε, Hs00152928_
m1; CYP26A1, Hs00175627_m1; 18S endogenous 
control, 4333762F; RARβ2, Hs00977143_m1; Applied 
Biosystems). The amplimers and Taqman probes used for 
the reverse-transcriptase RT-PCR assays of RARα-v1 to 
RARα-v4 were obtained from Life Technologies Italia 
(Monza, Italy) as detailed in Supplementary Methods.
RARα1, RARα2 and PML-RAR transactivation
COS-7 cells were transfected with RARα1, RARα2 
and PML-RAR, alone or in combination in the presence 
of the RARE-containing β2RARE-luciferase reporter [64]. 
The normalization plasmid is a renilla luciferase construct 
(Promega) [63].
FACS analysis, antibodies, immuno-precipitation 
and WB analyses
CD11b, CD11c and CD38 surface markers were 
determined with a Fluorescence Activated Cell Sorter 
(FACS, Becton and Dickinson) [26, 32]. Rabbit anti-
RARα polyclonal antibodies [RPalpha(F)] and anti-
RARα1 mouse monoclonal antibodies [Ab10a(A1)] 
were previously described [65]. Anti-RARα2 mouse 
monoclonal antibodies were raised against a synthetic 
peptide (amino-acids 1-29). Both Ab10a(A1) and 
Ab25a(A2) were purified on sulfoLink gel columns 
(Pierce Chemical) coupled to the immunizing 
peptide [66]. The other anti-RARα (SC551), anti-
β-actin, cEBPβ, and anti-STAT-1 antibodies were 
from Santa-Cruz-Biotechnology. Anti-PU.1 and anti-
paxillin antibodies were from Cell Signaling and 
Transduction Laboratories, respectively. WB analyses 
were performed as previously described [26] [32]. 
Immuno-precipitations were performed with antibodies 
immobilized on Protein-G-sepharose (Amersham). 
Agarose beads coupled to anti-HA antibodies were from 
Sigma (A2095).
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Far-western and GST pull-down assays
COS-7 cells were transfected with a pcDNA3 
plasmid containing haemoagglutinin (HA)-tagged RARa2 
(pHA-RARα2). Extracts were precipitated with agarose-
conjugated anti-HA monoclonal antibodies. The immuno-
precipitates were subjected to Far-Western analysis using 
GST-tagged recombinant proteins [32]. For the pull-down 
experiments [32], we used the described GST-RARα1, 
GST-RARα2 and derived recombinant proteins. GST-
RARα2 was obtained from E. coli cells transformed with 
an appropriate RARα2 cDNA construct cloned in the 
EcoRI-Not1 sites of pGEX4T2. The recombinant proteins 
conjugated to Glutathione-sepharose beads (Amersham) 
were incubated with extracts of COS-7 cells transfected 
with pHA-RARα2, pHA-SNAIL, pcDNA3-RARα1, pSG5-
PML-RAR or pcDNA3 containing the HA-tag (pHA) and 
pcDNA3 plasmids, for 4 hours. Pulled-down proteins were 
subjected to WB analysis using anti-HA, anti-RARα or 
anti-GST antibodies.
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